Palbociclib – how a novel process development approach provides IP advantages
This whitepaper outlines how Dr. Reddy's holistic development approach can help our API partners across geographies to provide patients early access to the generic alternative of Palbocicilb while gaining or maintaining competitive advantages.
Our team of process experts draw on their integrated understanding of IP, process development (API and formulation), and API manufacturing to ensure that by design the process is lean, free from potential genotoxic impurities and scalable to manufacture for early market entries.
To continue on reading our latest whitepaer please fill the contact form below :
You can also explore our Palbocicilb API offering by clicking on the link below: